Experimental Treatment Offers New Hope in Treating Alzheimer’s Disease
Coping with an Alzheimer’s diagnosis can feel overwhelming and may trigger feelings of loss, grief, and helplessness. At The CRCNJ, we provide our patients and their families with the resources, support, and comprehensive care they need to manage a diagnosis while also empowering them to take an active role in their brain health. Whether you’ve been newly diagnosed with Alzheimer’s or have experienced unsuccessful treatment in the past, there are options available to you. New treatments aimed at stopping the progression of the disease are continually being researched by way of clinical trials, offering hope.
Alzheimer’s disease is a complicated process characterized by the production of amyloid plaque and neurofibrillary tangles in the brain. Neuroinflammation, slowed glucose metabolism, and other brain changes also play a role in the clinical manifestation of Alzheimer’s disease. As we learn more about the underpinnings of this disease, scientists are exploring different approaches to treatment.
New Experimental Treatment Available
At The CRCNJ, we are part of a network of research clinics testing a new experimental treatment called sodium oligomannate (GV-971), which targets the gut’s microbiome (all the bacteria in your gastrointestinal system). This naturally-derived, investigational medication may rebalance certain bacteria with the goal of reducing neuroinflammation; and, thereby, improving brain function and potentially slowing the progression of Alzheimer’s disease. This investigational medication has been approved in China for the treatment of Alzheimer’s disease. Green Memory is a Phase 3 study aimed towards providing ample data to the FDA for the potential approval of this medication within the United States.
Be Part of the Cure—How to Participate
The only way to find a cure is through clinical trials. Over 90% of Alzheimer’s research is slowed by lack of participation. If you are between the ages of 50 and 85 and have been diagnosed with mild-to-moderate Alzheimer’s disease, you may be eligible to participate in this new study assessing the effectiveness of sodium oligomannate (GV-971).
Learn if you qualify for this new experimental treatment by contacting us today.
